Isarna Therapeutics Attracts New Investment For Next-Generation Antisense Drugs
This article was originally published in The Pink Sheet Daily
Following a Phase III disappointment with its lead anticancer candidate, Germany’s Isarna Therapeutics has garnered new funding to advance its preclinical pipeline of oligonucleotides targeting TGF-beta.
You may also be interested in...
In the latest of a handful of big pharma RNA partnerships, Bristol-Myers and Santaris have entered into a broad discovery and development deal. For the biotech, it brings a new partner into the string of deals that continue to be its main source of capital.
The biotech’s latest tie-up is another validation of its technology that could help it garner further attention – and better economics – for some of its late-stage programs.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.